Neoleukin Therapeutics, Inc. (NASDAQ:NLTX – Get Free Report) was down 3% during mid-day trading on Monday. The company traded as low as $23.0750 and last traded at $23.55. 124,512 shares changed hands during trading, an increase of 149% from the average session volume of 50,104 shares. The stock had previously closed at $24.28.
Neoleukin Therapeutics Trading Down 3.0%
The company’s 50 day simple moving average is $31.95 and its 200 day simple moving average is $27.45. The stock has a market capitalization of $221.32 million, a PE ratio of -7.57 and a beta of 1.11.
About Neoleukin Therapeutics
Neoleukin Therapeutics, Inc was a biotechnology company focused on designing and developing computationally engineered immunotherapies for cancer and other serious diseases. The company used protein-engineering technologies to create novel cytokine therapies intended to stimulate the immune system while addressing limitations associated with naturally occurring cytokines.
Its leading product candidate was NL-201, a de novo protein designed to selectively activate pathways associated with interleukin-2 and interleukin-15.
See Also
- Five stocks we like better than Neoleukin Therapeutics
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
